ZENTALIS PHARMACEUTICALS INC

ZNTLNASDAQ

🏆 #2641 by market capEarnings Nov 9US Equity

$88.51▼ $0.55 (−0.62%)

Simulated price

1h—

24h▼ 0.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$350M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for ZNTL.

Trading Snapshot

Day Range: $88.22 – $89.09
52-Week Range: $1.21 – $6.95
Volume: $2.43B
Avg Volume: $2.99B
Shares Outstanding: 71.2M
Next Earnings: Oct 21, 2026

Fundamentals Snapshot

Annual Revenue: $41M
Last Q Revenue: $10M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.91
Dividend Yield: —

Why Investors Own ZNTL

✓High-growth profile — revenue up -3.2% YoY with expanding US Equity exposure.
✓Healthy economics — 76% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$41M▼ −6.1% YoY

Gross Margin (TTM)

76.3%▲ +0.9% YoY

Operating Income (TTM)

$10M▼ −6.1% YoY

Free Cash Flow (TTM)

$6M▼ −6.1% YoY

About ZENTALIS PHARMACEUTICALS INC

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

🦦